格隆汇10月14日｜强生(JNJ.US)预计财年销售额为935亿至939亿美元，此前预期为932亿至936亿美元。 ...

Core Insights - Johnson & Johnson raised its full-year sales outlook due to gains in both its prescription-drug and medical-device businesses in the latest quarter [1] Company Performance - The company reported an increase in sales across its prescription-drug segment, contributing positively to the overall financial outlook [1] - Gains in the medical-device business also played a significant role in enhancing the company's sales projections for the year [1]

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend. ...

强生10月14日发布第三季度业绩显示，销售额239.9亿美元，同比增长6.8%；调整后每股收益2.80美 元，上年同期2.42美元。强生预计全年销售额935亿美元至939亿美元，此前预计932亿美元至936亿美 元，仍然预测调整后每股收益10.80美元至10.90美元。 来源：智通财经 ...

Johnson & Johnson says it plans to separate its slower-growing orthopedics business from the rest of the company within 18 to 24 months https://t.co/jwAdzHkoWU ...

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20... ...

Core Insights - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,672 million in Q3 2025, with USD 2,088 million from the U.S. and USD 1,584 million from the rest of the world [1][5] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [2] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3]

Core Insights - Johnson & Johnson plans to separate its Orthopaedics business to enhance strategic focus and operational efficiency, aiming to drive value for stakeholders [1][2][3] - The standalone orthopaedics business, operating as DePuy Synthes, is set to become the largest and most comprehensive orthopaedics-focused company globally, with leading market share positions [2][5] Company Strategy - The separation is intended to strengthen Johnson & Johnson's focus on high-growth areas in Innovative Medicine and MedTech, optimizing its portfolio and enhancing value creation [2][3] - Post-separation, Johnson & Johnson will maintain leadership in six key growth areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision [3] Financial Outlook - The Orthopaedics business is projected to generate approximately $9.2 billion in sales for fiscal year 2024, addressing a global market opportunity exceeding $50 billion [5] - The separation is expected to improve top-line growth and operating margins for both Johnson & Johnson and DePuy Synthes [3][5] Leadership Changes - Namal Nawana has been appointed as Worldwide President of DePuy Synthes, effective immediately, and will lead the business through the separation process [6][9] - Nawana brings extensive experience in leading global medical device companies, having previously held senior roles at Smith & Nephew and Alere [8][9] Transaction Details - The company aims to complete the separation within 18 to 24 months, subject to various conditions including regulatory approvals and board approval [10] - Johnson & Johnson will continue to operate its Orthopaedics business in alignment with its current strategy during the separation process [11]

Core Viewpoint - The planned separation is part of Johnson & Johnson's strategy to streamline operations and concentrate on faster-growing business segments [1] Group 1 - Johnson & Johnson is executing a separation to enhance focus on its core, high-growth areas [1]

Core Viewpoint - Johnson & Johnson reported strong performance in Q3 2025, driven by a robust portfolio and progress in key therapeutic areas, indicating a new era of growth and innovation [1]. Overall Financial Results - The company does not provide GAAP financial measures on a forward-looking basis due to uncertainties related to legal proceedings and other factors [5]. Regional Sales Results - Specific regional sales results were not detailed in the provided content. Segment Sales Results Innovative Medicine - Worldwide operational sales grew by 5.3%, with net acquisitions and divestitures contributing positively by 1.6% due to CAPLYTA [3]. - Key growth drivers included DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience [3]. - Growth was partially offset by a negative impact of approximately 1,070 basis points from STELARA in Immunology and IMBRUVICA in Oncology [3]. MedTech - Worldwide operational sales increased by 5.6%, with net acquisitions and divestitures negatively impacting growth by 0.1% [4]. - Growth was primarily driven by electrophysiology products, Abiomed, Shockwave in Cardiovascular, wound closure products in General Surgery, and Surgical Vision [4]. Notable Announcements in the Quarter - The company encourages reviewing its disclosures filed with the Securities and Exchange Commission for additional context [7]. Webcast Information - Johnson & Johnson will conduct a conference call with investors to discuss the earnings release, accessible via their website [8]. About Johnson & Johnson - The company emphasizes its commitment to healthcare innovation, aiming to prevent, treat, and cure complex diseases through its expertise in Innovative Medicine and MedTech [9].